Contact
searchSearch
HMP Global

Pharmacy Learning Network

PharmLaw

PharmLaw
Eli Lilly Files Lawsuits Targeting Alleged Sales of Unapproved Retatrutide
08/12/2026
Hannah Musick
Eli Lilly has filed 6 lawsuits against companies allegedly selling unapproved versions of investigational obesity drug retatrutide, highlighting growing legal and regulatory scrutiny of unauthorized products entering the rapidly expanding...
Eli Lilly has filed 6 lawsuits against companies allegedly selling unapproved versions of investigational obesity drug retatrutide, highlighting growing legal and regulatory scrutiny of unauthorized products entering the rapidly expanding...
Eli Lilly has filed 6 lawsuits...
08/12/2026
Pharmacy Learning Network
PharmLaw
Arkansas Suspends Enforcement of Specialty Drug Distribution Law Following Constitutional Challenge
08/05/2026
Hannah Musick
The Arkansas State Board of Pharmacy has suspended enforcement of a law restricting manufacturers' use of limited drug distribution networks after a federal court found the statute likely violates the dormant Commerce Clause, setting up a...
The Arkansas State Board of Pharmacy has suspended enforcement of a law restricting manufacturers' use of limited drug distribution networks after a federal court found the statute likely violates the dormant Commerce Clause, setting up a...
The Arkansas State Board of...
08/05/2026
Pharmacy Learning Network
PharmLaw
EyePoint Pharmaceuticals Agrees to $4.6 Million False Claims Act Settlement
07/29/2026
Grace Taylor, MS, MA
EyePoint Pharmaceuticals has agreed to pay $4.6 million to resolve False Claims Act allegations involving DEXYCU marketing practices, highlighting continued federal scrutiny of pharmaceutical manufacturer programs under the Anti-Kickback...
EyePoint Pharmaceuticals has agreed to pay $4.6 million to resolve False Claims Act allegations involving DEXYCU marketing practices, highlighting continued federal scrutiny of pharmaceutical manufacturer programs under the Anti-Kickback...
EyePoint Pharmaceuticals has...
07/29/2026
Pharmacy Learning Network
PharmLaw
Florida Laboratory to Pay $9.8 Million to Resolve FCA Allegations Over Physician Compensation
07/22/2026
Grace Taylor, MS, MA
A Florida laboratory agreed to pay $9.8 million to resolve False Claims Act (FCA) allegations involving physician compensation arrangements that allegedly violated the Stark Law, highlighting ongoing federal scrutiny of referral-based...
A Florida laboratory agreed to pay $9.8 million to resolve False Claims Act (FCA) allegations involving physician compensation arrangements that allegedly violated the Stark Law, highlighting ongoing federal scrutiny of referral-based...
A Florida laboratory agreed to...
07/22/2026
Pharmacy Learning Network
PharmLaw
FTC Settlement With Caremark Signals New Compliance Expectations for PBMs
07/15/2026
Hannah Musick
The Federal Trade Commission's (FTC) proposed settlement with CVS Caremark would require significant changes to pharmacy benefit manager (PBM) rebate practices, transparency, formulary management, and pharmacy contracting, signaling evolving...
The Federal Trade Commission's (FTC) proposed settlement with CVS Caremark would require significant changes to pharmacy benefit manager (PBM) rebate practices, transparency, formulary management, and pharmacy contracting, signaling evolving...
The Federal Trade Commission's...
07/15/2026
Pharmacy Learning Network

FDA Recalls

News
Mirabegron Tablets Recalled Due to CGMP Deviations
08/13/2026
Rebecca Amrick
Mirabegron extended-release tablets are under a voluntary Class II recall after an N-nitroso mirabegron impurity was found in the product, violating Current Good Manufacturing Practice specifications.
Mirabegron extended-release tablets are under a voluntary Class II recall after an N-nitroso mirabegron impurity was found in the product, violating Current Good Manufacturing Practice specifications.
Mirabegron extended-release...
08/13/2026
Pharmacy Learning Network
News
Dicyclomine Hydrochloride Recalled Due to Empty Capsules
08/13/2026
Rebecca Amrick
A voluntary Class II recall has been issued for dicyclomine hydrochloride due to reports of empty capsules, affecting 6408 bottles.
A voluntary Class II recall has been issued for dicyclomine hydrochloride due to reports of empty capsules, affecting 6408 bottles.
A voluntary Class II recall has...
08/13/2026
Pharmacy Learning Network
News
Cyclophosphamide Injection Recalled Due to the Presence of Steel Particles
08/13/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class I recall for cyclophosphamide injection due to the presence of steel particles, affecting 5541 vials.
The US Food and Drug Administration (FDA) has issued a Class I recall for cyclophosphamide injection due to the presence of steel particles, affecting 5541 vials.
The US Food and Drug...
08/13/2026
Pharmacy Learning Network
News
Dorzolamide and Timolol Ophthalmic Solution Recalled Due to Defective Containers
08/06/2026
Rebecca Amrick
Dorzolamide and timolol maleate ophthalmic solution is subject to a voluntary Class II recall after the firm received complaints about defective containers.
Dorzolamide and timolol maleate ophthalmic solution is subject to a voluntary Class II recall after the firm received complaints about defective containers.
Dorzolamide and timolol maleate...
08/06/2026
Pharmacy Learning Network
News
Azelaic Acid Gel Recalled Due to CGMP Deviations
08/06/2026
Rebecca Amrick
A voluntary Class II recall has been issued for azelaic acid gel due to Current Good Manufacturing Practice (CGMP) deviations, resulting from the product’s abnormal texture.
A voluntary Class II recall has been issued for azelaic acid gel due to Current Good Manufacturing Practice (CGMP) deviations, resulting from the product’s abnormal texture.
A voluntary Class II recall has...
08/06/2026
Pharmacy Learning Network

In the News

News
Mirabegron Tablets Recalled Due to CGMP Deviations
08/13/2026
Rebecca Amrick
Mirabegron extended-release tablets are under a voluntary Class II recall after an N-nitroso mirabegron impurity was found in the product, violating Current Good Manufacturing Practice specifications.
Mirabegron extended-release tablets are under a voluntary Class II recall after an N-nitroso mirabegron impurity was found in the product, violating Current Good Manufacturing Practice specifications.
Mirabegron extended-release...
08/13/2026
Pharmacy Learning Network
News
Dicyclomine Hydrochloride Recalled Due to Empty Capsules
08/13/2026
Rebecca Amrick
A voluntary Class II recall has been issued for dicyclomine hydrochloride due to reports of empty capsules, affecting 6408 bottles.
A voluntary Class II recall has been issued for dicyclomine hydrochloride due to reports of empty capsules, affecting 6408 bottles.
A voluntary Class II recall has...
08/13/2026
Pharmacy Learning Network
News
Cyclophosphamide Injection Recalled Due to the Presence of Steel Particles
08/13/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class I recall for cyclophosphamide injection due to the presence of steel particles, affecting 5541 vials.
The US Food and Drug Administration (FDA) has issued a Class I recall for cyclophosphamide injection due to the presence of steel particles, affecting 5541 vials.
The US Food and Drug...
08/13/2026
Pharmacy Learning Network
PharmLaw
Eli Lilly Files Lawsuits Targeting Alleged Sales of Unapproved Retatrutide
08/12/2026
Hannah Musick
Eli Lilly has filed 6 lawsuits against companies allegedly selling unapproved versions of investigational obesity drug retatrutide, highlighting growing legal and regulatory scrutiny of unauthorized products entering the rapidly expanding...
Eli Lilly has filed 6 lawsuits against companies allegedly selling unapproved versions of investigational obesity drug retatrutide, highlighting growing legal and regulatory scrutiny of unauthorized products entering the rapidly expanding...
Eli Lilly has filed 6 lawsuits...
08/12/2026
Pharmacy Learning Network
News
Dorzolamide and Timolol Ophthalmic Solution Recalled Due to Defective Containers
08/06/2026
Rebecca Amrick
Dorzolamide and timolol maleate ophthalmic solution is subject to a voluntary Class II recall after the firm received complaints about defective containers.
Dorzolamide and timolol maleate ophthalmic solution is subject to a voluntary Class II recall after the firm received complaints about defective containers.
Dorzolamide and timolol maleate...
08/06/2026
Pharmacy Learning Network

Subscribe Today

Pharmacy Learning Network Newsletter

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use